UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2002 or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ________to _________
Commission file number: 0-32259
Align Technology, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
821 Martin Avenue
Santa Clara, California 95050
(408) 470-1000
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES [X] NO [ ].
The number of shares of the Registrant's Common Stock outstanding as of October 31, 2002 was 48,129,176.
Align Technology, Inc.
TABLE OF CONTENTS
| PART I. Financial Information | Page No. |
| Item 1. Condensed Consolidated Financial Statements (unaudited) |
|
|
Condensed Consolidated Balance Sheets as of September 30, 2002 and December 31, 2001 |
|
|
Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2002 and 2001 |
|
|
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2002 and 2001 |
|
| Notes to Condensed Consolidated Financial Statements |
|
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations |
|
| Item 3. Quantitative and Qualitative Disclosures About Market Risk |
|
| Item 4. Controls and Procedures |
|
| PART II. Other Information |
|
| Item 1. Legal Proceedings |
|
| Item 2: Changes in Securities |
|
| Item 3: Defaults Upon Senior Securities |
|
| Item 4: Submission of Matters to a Vote of Security Holders |
|
| Item 5: Other Information |
|
| Item 6. Exhibits and Reports on Form 8-K |
|
| Signatures |
|
| Certifications |
|
| Index to Exhibits |
|
PART I -- FINANCIAL INFORMATION
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
ALIGN TECHNOLOGY, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
(UNAUDITED)
September 30, December 31,
2002 2001
------------- -------------
ASSETS
Current assets:
Cash and cash equivalents........................... $ 16,746 $ 50,550
Restricted cash..................................... 373 723
Marketable securities, short-term................... 5,665 12,494
Accounts receivable, net............................ 16,072 11,556
Inventories......................................... 1,461 1,549
Deferred costs...................................... 958 714
Other current assets................................ 6,343 3,997
------------- -------------
Total current assets............................... 47,618 81,583
Property and equipment, net......................... 28,734 32,021
Marketable securities, long-term.................... -- 2,627
Other assets........................................ 2,237 1,987
------------- -------------
Total assets....................................... $ 78,589 $ 118,218
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable.................................... $ 1,941 $ 4,376
Other accrued liabilities........................... 11,697 11,909
Deferred revenue.................................... 2,016 1,551
------------- -------------
Total current liabilities.......................... 15,654 17,836
Capital lease obligations, net of current portion.... 644 980
Contingencies (Note 4)
Stockholders' equity:
Common stock........................................ 5 5
Additional paid-in capital.......................... 347,355 355,055
Deferred stock-based compensation................... (23,722) (48,324)
Notes receivable from stockholders.................. (1,096) (1,484)
Accumulated other comprehensive income ............. 33 226
Accumulated deficit................................. (260,284) (206,076)
------------- -------------
Total stockholders' equity......................... 62,291 99,402
------------- -------------
Total liabilities and stockholders' equity......... $ 78,589 $ 118,218
============= =============
The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.
ALIGN TECHNOLOGY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(UNAUDITED)
Three Months Ended Nine Months Ended
September 30, September 30,
-------------------- --------------------
2002 2001 2002 2001
--------- --------- --------- ---------
Revenues.................................... $ 18,573 $ 12,912 $ 52,969 $ 34,084
Cost of revenues............................ 10,880 11,265 34,159 36,649
--------- --------- --------- ---------
Gross profit (loss)....................... 7,693 1,647 18,810 (2,565)
--------- --------- --------- ---------
Operating expenses:
Sales and marketing....................... 10,870 11,940 32,136 39,596
General and administrative................ 10,547 9,289 31,650 24,253
Research and development.................. 2,997 3,444 9,096 11,204
Litigation settlement..................... -- -- -- 400
--------- --------- --------- ---------
Total operating expenses.................... 24,414 24,673 72,882 75,453
--------- --------- --------- ---------
Loss from operations........................ (16,721) (23,026) (54,072) (78,018)
Interest and other income (expense), net.... (169) 523 (136) 1,263
--------- --------- --------- ---------
Net loss.................................... (16,890) (22,503) (54,208) (76,755)
Dividend related to beneficial conversion
feature of preferred stock................. -- -- -- (11,191)
--------- --------- --------- ---------
Net loss available to common stockholders... $ (16,890) $ (22,503) $ (54,208) $ (87,946)
========= ========= ========= =========
Net loss available to common stockholders,
basic and diluted.......................... $ (0.36) $ (0.50) $ (1.16) $ (2.14)
========= ========= ========= =========
Shares used in computing net loss per share
available to common stockholders, basic
and diluted................................ 46,934 45,035 46,556 41,098
========= ========= ========= =========
The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.
ALIGN TECHNOLOGY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(UNAUDITED)
Nine Months Ended
September 30,
----------------------
2002 2001
---------- ----------
Cash Flows from Operating Activities:
Net loss........................................................ $ (54,208) $ (76,755)
Adjustments to reconcile net loss to net cash
used in operating activities:
Amortization of deferred stock compensation................... 12,447 16,786
Compensation expense for accelerated vesting of stock options. 2,240 218
Stock-based compensation...................................... 1,781 --
Depreciation and amortization................................. 10,078 5,221
Loss on retirement of assets.................................. 3 35
Allowance for doubtful accounts............................... 712 1,231
Non-cash interest income on notes receivable.................. (45) (131)
Non-cash interest expense on convertible subordinated note.... -- 1,803
Non-cash accretion on marketable securities................... 66 (1,274)
Changes in Operating Assets and Liabilities:
Accounts receivable.......................................... (5,228) (6,134)
Deferred costs............................................... (244) 1,576
Inventories.................................................. 88 116
Other current assets......................................... (2,346) (1,263)
Accounts payable............................................. (2,435) (1,865)
Accrued liabilities.......................................... (234) (3,848)
Deferred revenue............................................. 465 (1,301)
---------- ----------
Net cash used in operating activities...................... (36,860) (65,585)
---------- ----------
Cash Flows from Investing Activities:
Purchase of property, plant and equipment....................... (6,794) (10,480)
Decrease in restricted cash..................................... 350 14,782
Purchase of marketable securities............................... (1,972) (72,088)
Proceeds from sales and maturities of marketable securities..... 11,169 70,249
Change in other assets.......................................... (250) (1,714)
---------- ----------
Net cash provided by investing activities.................. 2,503 749
---------- ----------
Cash Flows from Financing Activities:
Proceeds from issuance of common stock, net..................... 917 127,662
Proceeds from repayment of notes receivable from shareholders... 225 79
Repurchase of common stock...................................... (275) --
Payments on loan and capital leases............................. (314) (339)
---------- ----------
Net cash provided by financing activities.................. 553 127,402
---------- ----------
Net (decrease) increase in cash and cash equivalents............. (33,804) 62,566
Cash and cash equivalents at beginning of period................. 50,550 2,828
---------- ----------
Cash and cash equivalents at end of period....................... $ 16,746 $ 65,394
========== ==========
The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.
ALIGN TECHNOLOGY, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
financial statements as of September 30, 2002, and for the three months and nine
months ended September 30, 2002 and 2001, have been prepared in accordance with
accounting principles generally accepted in the United States of America for
interim financial statements and pursuant to the rules and regulations of the
Securities and Exchange Commission, and include the accounts of Align
Technology, Inc. and its wholly-owned subsidiaries (collectively "Align" or the
"Company"). Certain information and footnote disclosures normally included in
annual financial statements prepared in accordance with accounting principles
generally accepted in the United States of America have been condensed or
omitted pursuant to such rules and regulations. In the opinion of management,
the unaudited condensed consolidated financial statements reflect all
adjustments (consisting only of normal recurring adjustments) necessary for a
fair presentation of the financial position of the Company. These unaudited
condensed consolidated financial statements should be read in conjunction with
the Company's audited consolidated financial statements and notes for the year
ended December 31, 2001, included in the Company's Annual Report on Form 10-
K.
The results of operations for the three months and nine months ended September 30, 2002 are not necessarily indicative of results that may be expected for any other interim period or for the full fiscal year ending December 31, 2002. The condensed consolidated balance sheet at December 31, 2001 has been derived from the audited consolidated financial statements at that date, but does not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.
These financial statements contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has sustained significant losses each year since inception. There can be no assurance that the Company will be able to obtain additional debt or equity financing, if and when needed, on terms acceptable to the Company. Any additional equity or debt financing may involve substantial dilution to the Company's stockholders, restrictive covenants or high interest costs. The failure to raise needed funds on sufficiently favorable terms could have a material adverse effect on the Company's business, operating results and financial condition. If the Company is unable to obtain the financing it requires in future periods, the Company may be required to further reduce operating expenses by, including but not limited to, reducing planned capital expenditures relating to enhancing the Company's manufacturing process and reducing worldwide staff. The Company's long-term liquidity also depends upon its ability to increase revenues from the sale of its products and achieve profitability. The failure to achieve these goals could have a material adverse effect on the operating results and financial condition of the Company.
2. INVENTORIES
Inventories comprise (in thousands):
September 30, December 31,
2002 2001
----------- ---------
Raw materials....................................... $ 1,097 $ 1,122
Work in progress.................................... 215 182
Finished goods...................................... 149 245
----------- ---------
Total inventories................................... $ 1,461 $ 1,549
=========== =========
3. NET LOSS PER SHARE
Basic and diluted net loss per share is computed by dividing the net loss available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. The calculation of diluted net loss per share excludes potential shares of common stock if their effect is anti-dilutive. Potential common stock consists of common stock subject to repurchase, incremental common shares issuable upon the exercise of stock options.
The following is a reconciliation of the numerator (net loss available to common stockholders) and the denominator (number of shares) used in the basic and diluted net loss per share calculations (in thousands, except per share data):
Three Months Ended Nine Months Ended
September 30, September 30,
---------------------- --------------------
2002 2001 2002 2001
----------- --------- --------- ---------
Basic and diluted:
Net loss available to common stockholders........... $ (16,890) $ (22,503) $ (54,208) $ (87,946)
=========== ========= ========= =========
Weighted average common stock outstanding........... 47,988 47,880 47,950 44,300
Less: Weighted-average shares subject to repurchase. (1,054) (2,845) (1,394) (3,202)
----------- --------- --------- ---------
Weighted-average shares used in basic and diluted
net loss per share................................. 46,934 45,035 46,556 41,098
=========== ========= ========= =========
Net loss per share available to common stockholders. $ (0.36) $ (0.50) $ (1.16) $ (2.14)
=========== ========= ========= =========
The following table sets forth potential shares of common stock that are not included in the basic and diluted net loss per share available to common stockholders because to do so would be anti-dilutive (in thousands):
September 30,
-----------------------
2002 2001
----------- ---------
Options to purchase common stock.................... 7,650 5,583
Common stock subject to repurchase.................. 953 2,437
----------- ---------
8,603 8,020
=========== =========
4. CONTINGENCIES
On May 1, 2002, GW Com, Inc. filed a complaint in Santa
Superior Cour against us and James Lindsey, the owner of the premises located
at 851 Martin Avenue, Santa Clara, California. We were parties with GW Com to a
sub-sublease for such premises, the term of which expired on August 14, 2002.
In early 2001, we engaged in negotiations with GW Com to amend the sub-sublease
to add additional space and to extend the term through November 30, 2004.
The proposed amendment, however, required the consent of the owner of the subject
property, Mr. Lindsey. We withdrew from negotiations of the amendment, after,
among other things, Mr. Lindsey's consent could not be
obtained. GW Com's complaint against us and Mr. Lindsey alleges breach of
contract against us and breach of contract and intentional interference with
contract against Mr. Lindsey. In the complaint, GW Com seeks damages of more
than $4 million. The complaint is in its early stages and no trial date has
been set. We intend to vigorously contest GW Com's allegations.
On April 9, 2002, we exercised our right to
terminate an Exclusive Marketing Agreement dated October 18, 2001 with Discus
Dental Impressions, Inc. pursuant to the express terms of the Agreement and we
issued a press release reporting this termination. On or about May 14, 2002 we
received a demand for arbitration submitted by Discus Dental with the American
Arbitration Association in San Jose, California. In its arbitration demand,
Discus Dental seeks damages of approximately $30 million, including commissions
and bonus payments it claims it would have received under the Agreement as well
as other expenses, attorneys' fees and injunctive relief to prevent us from
selling Invisalign to dentists in the U.S. and Canada. However, prior to
terminating the Agreement, we conducted a thorough review of the Agreement and
each party's performance thereunder. Based upon that review of the factual and
legal issues, we deny all claims made by Discus Dental in its demand and contend
that such claims are entirely without merit. In addition, on or about June 13,
2002 we submitted a counter-claim against Discus Dental in the arbitration seeking
damages of approximately $40 million arising out of our claims for
misrepresentation, breach of confidentiality provisions, and unfair competition,
among others. The three arbitrators have been recently selected, and the matter
is now set for arbitration on August 18, 2003. The Company was involved in a patent infringement proceeding
with a plaintiff asserting infringement of two of its patents. On June 30, 2000,
the Company entered into a stipulation of dismissal with the plaintiff whereby
the plaintiff agreed not to recommence a suit against the Company for two years
with respect to the disputed patents. Pursuant to the agreement, if a patent is
subsequently issued to the plaintiff and the plaintiff believes the Company is
infringing it, then the plaintiff may commence suit after one year from the
effective date of the agreement and include in such action claims involving the
two previously disputed patents. If any such action is successful, it could
result in a significant monetary damage judgment against the Company. The Company is subject to claims and assessments from time to
time in the ordinary course of business. Management does not believe that any
such matters, individually or in the aggregate, will have a material adverse
effect on the Company's financial condition, results of operations or cash
flows. 5. ACCUMULATED OTHER COMPREHENSIVE INCOME Accumulated other comprehensive income consists entirely
of the change in unrealized gains or losses on available-for-sale securities at
September 30, 2002 and December 31, 2001. 6. RESTRUCTURING In July 2002, the Company announced a
plan to streamline worldwide operations. The plan includes closing the
Company's facilities in Pakistan and the United Arab Emirates. The operations
performed at these facilities are being transitioned to the United States and
Costa Rica. In addition, the plan included a global reduction in worldwide
staff. The Company recorded severance charges relating to the plan of $1.8
million for the period ending September 30, 2002, of which $0.4 million were
included in accrued liabilities as of September 30, 2002. Remaining charges
related to the plan range from $4.8 million to $5.3 million. Our facility in
Pakistan ceased production on October 25, 2002. Our facility in the U.A.E. is
scheduled to cease production on December 13, 2002. It is estimated that the
remainder of operational activities relating to the plan will conclude during
the first quarter of 2003, although we will continue to engage in non-
operational activities in both Pakistan and the U.A.E. until we have disposed of
our assets in those countries. Included in the estimated remaining charges is approximately
$2.1 million of property, plant and equipment located at our Pakistan facility,
which represents the recorded net book value as of September 30, 2002. The
Company is currently in the process of obtaining an independent fair market
valuation of the property, plant and equipment. The Company is also in the
process of locating a buyer in Pakistan for the property, plant and equipment.
As of September 30, 2002, it is unknown whether the Company will be able to find
such a buyer. The Company has no alternative use for the property, plant and
equipment in Pakistan and, under Pakistani law, cannot move the assets outside
the country. 7. RECENT ACCOUNTING PRONOUNCEMENTS In August 2001, the Financial Accounting Standards Board
("FASB") issued Statement of Financial Accounting Standards No. 143,
("SFAS 143"), "Accounting for Asset Retirement Obligations,"
which is effective for fiscal years beginning after June 15, 2002. SFAS 143
addresses financial accounting and reporting for obligations associated with the
retirement of tangible long-lived assets and the associated asset retirement
costs. SFAS 143 applies to all entities. The Company believes that the
adoption of SFAS 143 will not have a material impact on the consolidated
financial position or results of operations of the Company. In April 2002, the FASB issued Statement of
Financial Accounting Standards No. 145 ("SFAS 145"), "Rescission
of FASB Statements No. 4, 44 and 64, Amendment of FASB Statement No. 13, and
Technical Corrections," which is effective for fiscal years beginning after
May 15, 2002. Under SFAS 145, gains and losses from the extinguishment of debt
should be classified as extraordinary items only if they meet the criteria of
Accounting Principles Board Opinion No. 30. SFAS also addresses financial
accounting and reporting for capital leases that are modified in such a way as
to give rise to a new agreement classified as an operating lease. The Company
believes that the adoption of SFAS 145 will not have a material impact on the
consolidated financial position or results of the operations of the Company. In June 2002, the FASB issued Statement of Financial
Accounting Standards No. 146 ("SFAS 146"), "Accounting for Costs
Associated with Exit or Disposal Activities," which is effective for exit
or disposal activities initiated after December 31, 2002. SFAS 146 nullifies
Emerging Issues Task Force Issue No. 94-3, "Liability Recognition for
Certain Employee Termination Benefits and Other Costs to Exit an Activity
(including Certain Costs Incurred in a Restructuring)." Under SFAS 146, a
liability is required to be recognized for a cost associated with an exit or
disposal activity when the liability is incurred. SFAS 146 applies to costs
associated with an exit activity that does not involve an entity newly acquired
in a business combination or with a retirement or disposal activity covered by
FASB Statements No. 143 and 144. The Company adopted SFAS during the quarter ended
September 30, 2002, and it did not have a material impact on the consolidated financial position or
results of the operations of the Company. ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS This quarterly report contains certain forward-
looking statements (as such term is defined in Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934) and information
relating to the Company that are based on the beliefs of the management of the
Company as well as assumptions made by and information currently available to
the management of the Company. For example, statements that are not based on
historical facts, which can be identified by the use of such words as "likely,"
"will," "suggests," "target," "may," "would," "could," "anticipate," "believe,"
"estimate," "expect," "intend," "plan," "predict," and similar expressions and
their variants, are forward-looking. Such statements reflect the judgment of the
Company as of the date of this quarterly report and they involve many risks and
uncertainties, such as those described below and those contained in "Factors
That May Affect Future Operating Results." These factors could cause actual
results to differ materially from those predicted in any forward-looking
statements. Although we believe that the expectations reflected in the forward-
looking statements are reasonable, we cannot guarantee future results, levels of
activity, performance or achievements. Moreover, neither we nor any other person
assumes responsibility for the accuracy and completeness of these forward-
looking statements. The Company undertakes no obligation to update forward-
looking statements. The following discussion and analysis should be
read in conjunction with the condensed consolidated financial statements and the
notes thereto included in Item 1 in this quarterly report and our audited
consolidated financial statements and notes for the year ended December 31,
2001, included in the Company's Annual Report on Form 10-K. Overview From our inception in April 1997, we were engaged in the
design, manufacture and marketing of Invisalign, a proprietary new system for
treating malocclusion, or the misalignment of teeth. In July 1999, we commenced
commercial sales of Invisalign. Prior to July 1999, we devoted nearly all our
resources to developing our software and manufacturing processes, performing
clinical trials of Invisalign and building our sales force, customer support and
management teams. We exited the development stage in July 2000. Invisalign has two components: ClinCheck and Aligners.
ClinCheck is an Internet-based application that allows dental professionals to
simulate treatment, in three dimensions, by modeling two-week stages of tooth
movement. Aligners are thin, clear plastic, removable dental appliances that are
manufactured in a series to correspond to each two-week stage of the ClinCheck
simulation. Aligners are customized to perform the treatment prescribed for an
individual patient by a dental professional using ClinCheck. While our expansion outside of our domestic market (U.S. and
Canada) is still in the initial stages, we do incur substantial operating costs
outside of our domestic market. Currently, two of our key production steps are performed in
operations located outside of the U.S. At our facilities in Costa Rica and the
United Arab Emirates, or the U.A.E., technicians use a sophisticated, internally
developed computer-modeling program to prepare electronic treatment plans, which
are transmitted electronically back to the U.S. Previously, these steps were
also performed in our facility in Pakistan. These electronic files form the
basis of our ClinCheck product and are used for the manufacture of Aligner
molds. In addition, a third party manufacturer in Mexico fabricates and
performs finishing work on completed Aligners and ships the completed products
to our customers. Our costs associated with these operations are denominated in
Costa Rican colons, U.A.E. dirhams, and Mexican pesos. Our reliance on
international operations exposes us to risks and uncertainties that may affect
our business or results of operations including, among others, difficulties in
staffing and managing international operations, controlling quality of
manufacture, political, social and economic instability, acts of war or
terrorism, interruptions and limitations in telecommunication services, product
or material transportation delays or disruption, and trade restrictions and
changes in tariffs. However, we believe these risks in Costa Rica are mitigated
by the fact that our operations there do not involve the shipping or
manufacturing of any physical products, and in Mexico by the fact that our
operations there are governed under the provisions of the North American Free
Trade Agreement, or NAFTA. In July 2002, the Company announced a plan to streamline
worldwide operations. The plan includes closing the Company's facilities in
Pakistan and the U.A.E. The operations previously performed at these facilities
are being transitioned to the United States and Costa Rica. In addition, the
plan includes a global reduction in worldwide staff. Our facility in Pakistan
ceased production on October 25, 2002. Our facility in the U.A.E. is scheduled
to cease production on December 13, 2002. It is estimated that the remainder of
operational activities relating to the plan will conclude during the first
quarter of 2003, although we will continue to engage in non-operational
activities in both Pakistan and the U.A.E. until we have disposed of our assets
in those countries. We earn revenue primarily from the sale of Invisalign. We
charge dental professionals for the Invisalign case upon shipment of the
Aligners. All of the revenues associated with a given case, including ClinCheck
fees, are recognized at the time the Aligners are shipped. The costs of
producing the ClinCheck treatment plan, which are incurred prior to the
production of Aligners, are deferred and recognized as related revenue is
earned. In the event a dental professional does not proceed with Invisalign
beyond ClinCheck, we charge a fixed fee for the treatment simulation. This fee
is invoiced upon expiration or cancellation of the ClinCheck treatment
simulation plan, and the related revenue is recognized upon invoicing. We also
earn revenue when during the course of treatment, the refinement of a ClinCheck
treatment plan, known as case refinement, requires the manufacture of new
Aligners. We offer our dental professionals an optional enhanced warranty to
cover any required case refinement. In cases covered by the enhanced warranty,
the revenues associated with case refinement are recognized ratably over the
duration of the treatment plan. In cases where the dental professional has
declined to purchase the warranty coverage, case refinement revenues are
recognized when the new Aligners are shipped. We believe that the frequency of
case refinement will increase as clinical acceptance of Invisalign and its use
in complex cases increases. This increased frequency may lead to changes in how
we price refinement, which could in turn lead to changes in how we recognize
revenue related to case refinement. In any Invisalign case where we expect a
net loss, the entire loss is recognized immediately. Results of Operations Revenues. Revenues for the quarter ended September
30, 2002 increased 44% to $18.6 million, compared with $12.9 million for the
quarter ended September 30, 2001. Revenues for the nine-month period ended
September 30, 2002 increased 55% to $53.0 million, compared with $34.1 million
for the same nine-month period in 2001. The increase in revenues was primarily
due to the increase in Invisalign cases shipped, and for the nine-month period
ended September 30, 2002 an increase in training revenue of $3.6 million.
Substantially all of our training revenue was derived from our agreement with
Discus Dental, which was cancelled in April 2002. As a result, training revenue
for the quarter ended June 30, 2002 decreased by $1.7 million from the previous
quarter. We commenced direct training of general practice dentists in the
latter half of the quarter ending June 30, 2002. Although we expect training
revenue to increase in future periods, we expect the majority of our revenues
will be comprised of Invisalign revenue. Cost of revenues. Cost of revenues for the quarter
ended September 30, 2002 was $10.9 million, compared with $11.3 million for the
quarter ended September 30, 2001. Cost of revenues for the nine-month period
ended September 30, 2002 was $34.2 million, compared with $36.6 million for the
same nine-month period in 2001. Cost of revenues includes the salaries of staff
involved in production, the cost of materials and packaging used in production
and shipping, depreciation on the capital equipment used in the production
process, unabsorbed manufacturing capacity, training costs and an allocation of
the cost of facilities. Gross margin for the quarter ended September 30, 2002
increased to 41%, compared with 13% for the quarter ended September 30, 2001.
Gross margin for the nine-month period ended September 30, 2002 increased to
36%, compared with a negative gross margin of 8% for the same nine-month period
in 2001. We achieved positive gross margins mainly due to efficiencies achieved
in manufacturing as well as reducing overcapacity in many areas. Our gross
margin is affected by changes in manufacturing volume, manufacturing capacity
and changes in our pricing policies. Sales and marketing expenses. Sales and marketing
expenses for the quarter ended September 30, 2002 were $10.9 million, compared
with $11.9 million for the quarter ended September 30, 2001. Sales and
marketing expenses for the nine-month period ended September 30, 2002 were $32.1
million, compared with $39.6 million for the same nine-month period in 2001.
Sales and marketing expenses include sales force compensation together with
expenses of professional marketing, conducting training workshops and market
surveys, advertising and attending dental professional trade shows. The decrease
in sales and marketing expenses for the three-month period ended September 30,
2002 resulted primarily from decreased direct mail advertising of approximately
$1.4 million, partially offset by increases in payroll related expenses of $0.5
million due to increased headcount related to our direct sales force. The
decrease in sales and marketing expenses for the nine-month period ended
September 30, 2002 resulted primarily from decreases in media and advertising
expenses of approximately $13.2 million and decreases in direct mail advertising
of approximately $1.3 million. Partially offsetting these decreases were
increases in sales and marketing expenses at our international locations of
approximately $6.2 million and increases in payroll and related expenses of $0.9
million due to the increased headcount related to our direct sales force. General and administrative expenses. General and
administrative expenses for the quarter ended September 30, 2002 were $10.5
million, compared with $9.3 million for the quarter ended September 30, 2001.
General and administrative expenses for the nine-month period ended September
30, 2002 were $31.7 million, compared with $24.3 million for the same nine-month
period in 2001. General and administrative expenses include costs for the
compensation of administrative personnel, outside consulting services,
facilities, legal expenses and general corporate expenses. The increase in
general and administrative expenses for the three month period ended September
30, 2002 resulted primarily from an increase in expenses of approximately $1.6
million due to the growth of our international operations. The increase in
general and administrative expenses for the nine month period ended September
30, 2002 resulted primarily from increased expenses of approximately $5.2
million related to the growth of our international operations and increases in
payroll and related expenses of approximately $3.0 million due to increased
headcount at our corporate headquarters to support being a public company.
These increases were partially offset by decreased professional services of
approximately $0.9 million. Research and development expenses. Research and
development expenses for the quarter ended September 30, 2002 were $3.0 million,
compared with $3.4 million for the quarter ended September 30, 2001. Research
and development expenses for the nine-month period ended September 30, 2002 were
$9.1 million, compared with $11.2 million for the same nine-month period in
2001. Research and development expenses include the costs associated with
software engineering, the costs of designing, developing and testing our
products and the conduct of both clinical and post-marketing trials. We expense
our research and development costs as they are incurred. The decrease in
research and development expenses for the three-month period ended September 30,
2002 was primarily due to a decrease in payroll and related expenses of
approximately $0.5 million due to decreased headcount. The decrease in research
and development expenses for the nine-month period ended September 30, 2002 was
primarily due to a decrease in outside consulting services of approximately $1.4
million and a decrease in payroll and related expenses of approximately $1.0
million due to decreased headcount. Litigation settlement expenses. Litigation settlement
expenses resulted from a settlement of a class action lawsuit. In February
2001, a class action lawsuit was filed on behalf of all licensed dentists
(excluding orthodontists) in the U.S. The complaint alleged that Align's policy
of selling the Invisalign System exclusively to orthodontists violated the U.S.
antitrust laws. Without admitting any wrongdoing and pending approval from the
court and the completion of definitive documentation, the Company reached an
agreement in principle with the plaintiffs to settle the lawsuit. The remaining
total legal and other settlement costs that Align agreed to pay were
approximately $0.4 million. Pursuant to the settlement, Align will undertake to
train and certify 5,000 general practice dentists each year over the next four
years. Interest and other income (expense), net. Interest and
other expense was $0.2 million for the quarter ended September 30, 2002 compared
to interest and other income of $0.5 million for the quarter ended September 30,
2001. Interest and other expense for the nine month period ended September 30,
2002 was $0.1 million, compared with interest and other income of $1.3 million
for the same nine-month period in 2001. Other expense for 2002 consisted of
bank service charges related to credit card processing. Offsetting these
charges was decreasing interest income in 2002, primarily due to the decrease in
the Company's cash and cash equivalent balance and marketable securities
balances. Interest income for the nine months ended September 30, 2001 was
primarily generated from the Company's cash and cash equivalents balance and
investments in short-term marketable securities. Offsetting this income in the
first quarter of 2001 was non-cash interest expense of $1.8 million, recorded
in January 2001, related to the beneficial conversion feature embedded in
convertible subordinated notes. Dividend related to beneficial conversion feature of
preferred stock. In 2000 we issued 9,535,052 shares of Series D preferred
stock which were subject to an antidilution conversion price adjustment feature
which we triggered when we granted options to purchase our common stock beyond
the number of options that were authorized under our 1997 Plan at the time we
commenced our Series D preferred stock offering in May 2000. The conversion
feature provided that if, during the period between May 12, 2000 (the commitment
date for our Series D preferred stock offering) and the earlier of the closing
of an initial public offering or January 31, 2001, we had granted more than an
aggregate of 3,331,978 options to purchase our common stock, then the conversion
price of our Series D preferred stock would be adjusted downward from its
original conversion price of $10.625 per share. As of the end of January 2001,
we had granted an aggregate of 3,591,458 options to purchase shares of our
common stock in excess of the 3,331,978 options permitted, and we were therefore
required to issue an additional 790,342 shares of common stock upon the
conversion of the Series D preferred stock. These shares were in addition to
the 419,700 additional shares of common stock that we were required to
issue upon conversion of the Series D preferred stock as of December 31, 2000.
As a result, we recorded a deemed dividend for the three months ended March 31,
2001 based on the fair value of the common stock at the commitment date of the
Series D preferred stock offering of $11.2 million related to the preferred
stock sold and a charge to interest expense of $1.8 million for the beneficial
conversion feature embedded in convertible subordinated notes that were
previously converted. Stock-based compensation. In connection with the grant
of stock options to employees and non-employees, we recorded deferred stock-
based compensation as a component of stockholders' equity. Deferred stock-based
compensation for options granted to employees is the difference between the fair
value of our common stock on the date such options were granted and their
exercise price. For stock options granted to non-employees, the fair value of
the options, estimated using the Black-Scholes valuation model, is initially
recorded on the date of grant. As the non-employee options become exercisable,
we revalue the remaining unvested options, with the change in fair value from
period to period represented as a change in the deferred compensation charge.
This stock-based compensation is amortized as charges to operations over the
vesting periods of the options. We recorded amortization of deferred
compensation of $3.8 million and $5.0 million for the quarters ended September
30, 2002 and 2001, respectively. For the nine month periods ended September 30,
2002 and 2001, we recorded amortization of deferred compensation of $12.4
million and $16.8 million, respectively. Additionally, we recorded expenses of
$0.3 million for the quarter ended September 30, 2002 and $1.8million for the
nine month period ended September 30, 2002, related to options granted to non-
employees during the current fiscal year. The Company accelerated the vesting of options to several
employees in connection with severance packages. The accelerations were
accounted for as a charge to the statement of operations. The charge was $0.9
million for the quarter ended September 30, 2002 and $0.2 million for the
quarter ended September 30, 2001. For the nine month periods ended September
30, 2002 and 2001, we recorded $2.2 million and $0.2 million, respectively. The
charge is equal to the intrinsic value difference between the exercise price of
the accelerated options and the fair value of the common stock on the date of
acceleration. Historically, we have funded our operations with
the proceeds from the sale of our common and preferred stock, equipment leases
and bridge loans. As of September 30, 2002, we had $22.4 million in cash and
cash equivalents and marketable securities and an accumulated deficit of $260.3
million. Additionally, we had $0.4 million of restricted cash. Net cash used in operating activities totaled $36.9 million
and $65.6 million for the nine-month periods ended September 30, 2002 and 2001,
respectively. In each of these periods, net cash used by operating activities
consisted primarily of net operating losses and increases in accounts receivable
balances, partially offset by increases in depreciation and amortization, and
amortization of deferred stock-based compensation. Net cash provided by investing activities totaled $2.5
million for the nine month period ended September 30, 2002 and $0.7 million for
the nine month period ended September 30, 2001. For the nine month period ended
September 30, 2002, net cash provided by investing activities consisted
primarily of sales and maturities of marketable securities, partially offset by
purchases of property and equipment. For the nine month period ended September
30, 2001, net cash provided by investing activities consisted primarily of
proceeds from the sales and maturities of marketable securities and a decrease
in restricted cash, partially offset by purchases of marketable securities and
purchases of property and equipment. Net cash provided by financing activities was $0.6 million
and $127.4 million for the nine-month periods ended September 30, 2002 and 2001,
respectively. For the nine-month period ended September 30, 2001, net cash
provided by financing activities consisted primarily of proceeds from the
issuance of common stock. In January 2001, we completed our initial public
offering of 10 million shares of common stock. In March 2001, the underwriters
exercised an overallotment option for 628,706 shares. Net proceeds to us were
approximately $126.2 million. We expect that our operating expenses will increase with an
overall increase in the level of our business activity, including increased
sales and the related costs of products sold, our consumer advertising campaign
and dental professional marketing efforts, continuing efforts to automate our
manufacturing processes, increases in the size of our sales force and dental
professional training staff, continued international sales and marketing
efforts, and development and improvements to our product. In addition, we
may use cash to fund acquisitions of complementary businesses or technologies.
We believe it will be appropriate to obtain additional equity or debt financing
within the next 12 months. We may not be able to raise additional financing on
acceptable terms or at all. Recent Accounting Pronouncements In August 2001, the Financial Accounting Standards Board
("FASB") issued Statement of Financial Accounting Standards No. 143,
("SFAS 143"), "Accounting for Asset Retirement Obligations,"
which is effective for fiscal years beginning after June 15, 2002. SFAS 143
addresses financial accounting and reporting for obligations associated with the
retirement of tangible long-lived assets and the associated asset retirement
costs. SFAS 143 applies to all entities. The Company believes that the
adoption of SFAS 143 will not have a material impact on the consolidated
financial position or results of operations of the Company. In April 2002, the FASB issued Statement of Financial
Accounting Standards No. 145 ("SFAS 145"), "Rescission of FASB
Statements No. 4, 44 and 64, Amendment of FASB Statement No. 13, and Technical
Corrections," which is effective for fiscal years beginning after May 15,
2002. Under SFAS 145, gains and losses from the extinguishment of debt should
be classified as extraordinary items only if they meet the criteria of
Accounting Principles Board Opinion No. 30. SFAS also addresses financial
accounting and reporting for capital leases that are modified in such a way as
to give rise to a new agreement classified as an operating lease. The Company
believes that the adoption of SFAS 145 will not have a material impact on the
consolidated financial position or results of the operations of the Company. In June 2002, the FASB issued Statement of Financial
Accounting Standards No. 146 ("SFAS 146"), "Accounting for Costs
Associated with Exit or Disposal Activities," which is effective for exit
or disposal activities initiated after December 31, 2002. SFAS 146 nullifies
Emerging Issues Task Force Issue No. 94-3, "Liability Recognition for
Certain Employee Termination Benefits and Other Costs to Exit an Activity
(including Certain Costs Incurred in a Restructuring)." Under SFAS 146, a
liability is required to be recognized for a cost associated with an exit or
disposal activity when the liability is incurred. SFAS 146 applies to costs
associated with an exit activity that does not involve an entity newly acquired
in a business combination or with a retirement or disposal activity covered by
FASB Statements No. 143 and 144. The Company adopted SFAS 146 during the quarter ended
September 30, 2002, and it did not have a material impact on the consolidated financial position or
results of the operations of the Company. Factors That May Affect Future Operating Results Since we have a history of losses and negative operating cash flows, and
because we expect our operating losses to continue, we may not achieve or
maintain profitability in the future. We have incurred significant operating losses, negative
operating cash flows and have not achieved profitability. From inception through
July 2000, we spent significant funds in organizational and start-up activities,
recruiting key managers and employees, developing Invisalign and developing our
manufacturing and customer support resources. We also spent significant funds on
clinical trials and training programs to train dental professionals in the use
of Invisalign. We expect to have net losses and negative operating cash flows
for at least the next 12 months. We continue to incur significant operating expenses to:Liquidity and Capital Resources
As a result, we will need to increase our revenue significantly, while controlling our expenses, to achieve profitability. It is possible that we will not achieve profitability, and even if we do achieve profitability, we may not sustain or increase profitability in the future.
We may be unable to raise additional capital if it should be necessary, which could harm our ability to compete.
We have incurred significant operating losses and negative operating cash flows since inception and have not achieved profitability. As of September 30, 2002, we had an accumulated deficit of approximately $260.3 million.
We expect to expend significant capital to continue to build our national brand, expand our dental professional channel, automate our manufacturing processes and develop both product and process technology. The Company is in the process of obtaining debt financing in the form of an accounts receivable line of credit and an equipment line of credit. In addition, the Company is in the early stages of pursuing an equity financing. However, there can be no assurance that such additional financing will be available on a timely basis on terms acceptable to us, or at all, or that such financing will not be substantially dilutive to stockholders. If adequate funds are not available, we could be required to further reduce operating expenses by, including but not limited to, reducing planned capital expenditures relating to enhancing the Company's manufacturing process and reducing worldwide staff.
We have a limited operating history and expect our future financial results to fluctuate significantly, which may cause our stock price to decline.
We were incorporated in April 1997 and began sales of Invisalign in July 1999. Thus, we have a limited operating history, which makes an evaluation of our future prospects and your investment in our stock difficult. In addition, we expect our future quarterly and annual operating results to fluctuate as we increase our commercial sales. These fluctuations could cause our stock price to decline. Some of the factors that could cause our operating results to fluctuate include:
To respond to these and other factors, we may need to make business decisions that could adversely affect our operating results. Most of our expenses, such as employee compensation and lease payment obligations, are relatively fixed in the short term. Moreover, our expense levels are based, in part, on our expectations regarding future revenue levels. As a result, if our revenue for a particular period falls below our expectations, we may be unable to adjust spending quickly enough to offset any unexpected shortfall in revenue growth or any decrease in revenue levels.
Due to these and other factors, we believe that quarter-to- quarter comparisons of our operating results may not be meaningful. You should not rely on our results for any one quarter as an indication of our future performance.
We expect that revenue from the sale of Invisalign will continue to account for a substantial portion of our total revenue. Continued and widespread market acceptance of Invisalign is critical to our future success. Invisalign may not achieve market acceptance at the rate at which we expect, or at all, which could reduce our revenue.
If dental professionals do not adopt Invisalign in sufficient numbers or as rapidly as we anticipate, our operating results will be harmed.
As of September 30, 2002, approximately 7,400 dental professionals have submitted one or more cases to us. Our success depends upon increasing acceptance of Invisalign by dental professionals. Invisalign requires dental professionals and their staff to undergo special training and learn to interact with patients in new ways. In addition, because Invisalign has only been in clinical testing since July 1997 and commercially available since July 1999, dental professionals may be reluctant to adopt it until more historical clinical results are available. Also, increasing adoption by dental professionals will depend on factors such as the capability, safety, efficacy, ease of use, price, quality and reliability of our products and our provision of effective sales support, training and service. In the future, unanticipated poor clinical performance of Invisalign could result in significant adverse publicity and consequently in reduced acceptance by dental professionals. If Invisalign does not achieve growing acceptance in the orthodontic and dental communities, our operating results will be harmed.
If consumers do not adopt Invisalign in sufficient numbers or as rapidly as we anticipate, our operating results will be harmed.
Invisalign represents a significant change from traditional orthodontic treatment, and patients may be reluctant to accept it or may not find it preferable to conventional treatment. In addition, patients may not comply with recommended treatment guidelines which could compromise the effectiveness of their treatment. We have generally received positive feedback from both dental professionals and patients regarding Invisalign as both an alternative to braces and as a clinical method for treatment of malocclusion but a number of dental professionals believe that Invisalign is appropriate for only a limited percentage of their patients. Our success will depend upon the acceptance of Invisalign by the substantially larger number of dental professionals and potential patients to which we are now actively marketing. We have had a limited number of complaints from patients and prospective patients generally related to shipping delays and minor manufacturing irregularities. Market acceptance will depend in part upon the recommendations of dental professionals, as well as other factors including effectiveness, safety, reliability, improved treatment aesthetics and greater comfort and hygiene compared to conventional orthodontic products. Furthermore, consumers may not respond to our direct marketing campaigns or we may be unsuccessful in reaching our target audience. Adoption by consumers may also be impacted by general macroeconomic conditions, levels of consumer confidence and consumer spending, all of which could be effected by United States military action in Iraq. If consumers prove unwilling to adopt Invisalign as rapidly or in the numbers that we anticipate, our operating results will be harmed.
We are dependent on our international manufacturing operations, which exposes us to foreign operational, political and other risks that may harm our business.
Currently, two of our key production steps are performed in operations located outside of the U.S. At our facilities in Costa Rica and the U.A.E., where we create electronic treatment plans with the assistance of sophisticated software. Previously, these steps were also performed in our facility in Pakistan. In addition, we rely on third party manufacturers in Mexico to fabricate Aligners and to ship the completed product to customers. In July 2002, the Company announced a plan to streamline worldwide operations. The plan includes closing the Company's facilities in Pakistan and the U.A.E. The operations previously performed at these facilities are being transitioned to the United States and Costa Rica. In addition, the plan includes a global reduction in worldwide staff. Our facility in Pakistan ceased production on October 25, 2002. Our facility in the U.A.E. is scheduled to cease production on December 13, 2002. It is estimated that the remainder of operational activities relating to the plan will conclude during the first quarter of 2003, although we will continue to engage in non-operational activities in both Pakistan and the U.A.E. until we have disposed of our assets in those countries.
Our reliance on international operations exposes us to risks and uncertainties, including:
If any of these risks materialize in the future, our operating results may be harmed.
Our success depends in part on our proprietary technology and if we are unable to successfully enforce our intellectual property rights, our competitive position may be harmed.
Our success will depend in part on our ability to maintain existing intellectual property and to obtain and maintain further intellectual property protection for our products, both in the U.S. and in other countries. Our inability to do so could harm our competitive position. As of October 31, 2002, we have 23 issued U.S. patents and 61 pending U.S. patent applications. We have 20 foreign-issued patents and 114 pending foreign patent applications. We intend to rely on our portfolio of issued and pending patent applications in the U.S. and in other countries to protect a large part of our intellectual property and our competitive position. However, our currently pending or future patent filings may not issue as patents. Additionally, any patents issued to us may be challenged, invalidated, held unenforceable, circumvented, or may not be sufficiently broad to prevent third parties from producing competing products similar in design to our products. In addition, protection afforded by foreign patents may be more limited than that provided under U.S. patents and intellectual property laws. We also rely on protection of copyrights, trade secrets, know-how and proprietary information. We generally enter into confidentiality agreements with our employees, consultants and our collaborative partners upon commencement of a relationship with us. However, these agreements may not provide meaningful protection against the unauthorized use or disclosure of our trade secrets or other confidential information and adequate remedies may not exist if unauthorized use or disclosure were to occur. Our inability to maintain the proprietary nature of our technology through patents, copyrights or trade secrets would impair our competitive advantages and could have a material adverse effect on our operating results, financial condition and future growth prospects. In particular, a failure of our proprietary rights might allow competitors to copy our technology, which could adversely affect pricing and market share.
If we infringe the patents or proprietary rights of other parties, our ability to grow our business will be severely limited.
Extensive litigation over patents and other intellectual property rights is common in the medical device industry. We have been sued for infringement of another party's patent in the past and, while that action has been dismissed, we may be the subject of patent or other litigation in the future.
In January 2000, Ormco Corporation filed suit against us asserting an infringement of U.S. Patent Nos. 5,447,432 and 5,683,243. The complaint sought unspecified monetary damages and equitable relief. The complaint alleged that Invisalign infringed certain claims of the two patents relating to computer modeling of an ideal dentition and the production of orthodontic appliances based upon the ideal dentition. The suit has been dismissed but can be recommenced under certain circumstances. See "Part II-Item 1--Legal Proceedings." If the Ormco suit were recommenced and if Ormco were to prevail, we would have to seek a license from Ormco, which license might not be available on commercially reasonable terms or at all. In that event, we could be subject to damages or an injunction, which could materially adversely affect our business.
From time to time, we have received and may again receive letters from third parties drawing our attention to their patent rights. While we do not believe that we infringe any valid and enforceable rights which have been brought to our attention, there may be other more pertinent rights of which we are presently unaware. The defense and prosecution of intellectual property suits, interference proceedings and related legal and administrative proceedings could result in substantial expense to us and significant diversion of effort by our technical and management personnel. An adverse determination in a patent suit by Ormco or in any other litigation or interference proceeding to which we may become a party could subject us to significant liabilities. An adverse determination of this nature could also put our patents at risk of being invalidated or interpreted narrowly or require us to seek licenses from third parties. Licenses may not be available on commercially reasonable terms or at all, in which event, our business would be materially adversely affected.
We currently rely on third parties to provide key inputs to our manufacturing process, and if our access to these inputs is diminished, our business may be harmed.
We currently outsource key portions of our manufacturing process. We rely on a third party manufacturer in Mexico to fabricate Aligners and to ship the completed product to customers. As a result, if our third party manufacturer fails to deliver its components or if we lose its services, we may be unable to deliver our products in a timely manner and our business may be harmed. Finding a substitute manufacturer may be expensive, time-consuming or impossible.
In addition, we are highly dependent on manufacturers of specialized scanning equipment, rapid prototyping machines, resin and other advanced materials. We maintain single supply relationships for many of these machines and materials technologies. Our growth may exceed the capacity of these manufacturers to produce the needed equipment and materials in sufficient quantities to support our growth. In the event of delivery delays or shortages of these items, our business and growth prospects may be harmed.
We have experienced rapid growth, and our failure to manage this growth could harm our business.
We have expanded rapidly since we commenced commercial sales in 1999. Our headcount increased from approximately 50 employees as of September 30, 1999 to approximately 690 employees as of September 30, 2002. This expansion will continue to place significant demands on our management and other resources and will require us to continue to develop and improve our operational, financial and other internal controls both in the U.S. and internationally. In particular, rapid growth increases the challenges involved in a number of areas, including: recruiting and retaining sufficient skilled personnel, providing adequate training and supervision to maintain our high quality standards, and preserving our culture and values. Also, recent reductions in our workforce, although designed to not affect service levels and demand generation, may adversely affect these areas of our business. Our inability to effectively manage this level of growth would harm our business.
If we lose our key personnel or are unable to attract and retain key personnel, we may be
unable to pursue business opportunities or develop our products.We are highly dependent on the key employees in our clinical engineering and management teams. The loss of the services of those individuals may significantly delay or prevent the achievement of our product development and other business objectives and could harm our business. Our future success will also depend on our ability to identify, recruit, train and retain additional qualified personnel. In addition, few orthodontists are accustomed to working in a manufacturing environment since they are generally trained to work in private practices, universities and other research institutions. Thus, we may be unable to attract and retain personnel with the advanced qualifications necessary for the further development of our business. Furthermore, we may not be successful in retaining our key personnel or their services.
We experience competition from manufacturers of traditional braces and expect aggressive competition in the future.
Currently, we compete directly against a product called Red, White and Blue that is manufactured and distributed by Ormco, which is a subsidiary of Sybron Dental Specialities. In addition, manufacturers of traditional braces, such as 3M Company, Sybron Dental Specialities and Dentsply International, Inc. have substantially greater financial resources and manufacturing and marketing experience than we do and may, in the future, attempt to develop an orthodontic system similar to ours. Large consumer products companies may also enter the orthodontic supply market. Furthermore, we may face competition in the future from new companies that may introduce new technologies. We may be unable to compete with these competitors and one or more of these competitors may render our technology obsolete or economically unattractive. If we are unable to compete effectively with existing products or respond effectively to any products developed by our competitors, our business will be harmed.
Complying with the Food and Drug Administration (FDA) and other regulations is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.
Our products are medical devices and subject to extensive regulation in the U.S. and internationally. FDA regulations are wide ranging and govern, among other things:
Noncompliance with applicable regulatory requirements can result in enforcement action which may include recalling products, ceasing product marketing, and paying significant fines and penalties, which could limit product sales, delay product shipment and adversely affect our profitability.
In the U.S., we must comply with facility registration and product listing requirements of the FDA and adhere to applicable Quality System regulations. The FDA enforces its Quality System regulations through periodic unannounced inspections, which we have yet to undergo. If we or any third party manufacturer of our products do not conform to applicable Quality System regulations, we may be required to find alternative manufacturers, which could be a long and costly process.
Before we can sell a new medical device in the U.S., we must obtain FDA clearance or approval, which can be a lengthy and time-consuming process. Even though the devices we market have obtained the necessary clearances from the FDA through the pre-market notification provisions of Section 510(k) of the federal Food, Drug, and Cosmetic Act, we may be unable to maintain the necessary clearances in the future. Furthermore, we may be unable to obtain the necessary clearances for new devices that we market in the future.
Extensive and changing government regulation of the healthcare industry may be expensive to comply with and exposes us to the risk of substantial government penalties.
In addition to medical device laws and regulations, numerous state and federal healthcare-related laws regulate our business, covering areas such as:
Complying with these laws and regulations could be expensive and time-consuming, and could increase our costs or reduce or eliminate certain of our activities or our revenues.
We face risks related to our international sales, including the need to obtain necessary foreign regulatory clearance or approvals.
Sales of our products outside the U.S. are subject to foreign regulatory requirements that vary widely from country to country. The time required to obtain clearances or approvals required by other countries may be longer than that required for FDA clearance or approval, and requirements for such approvals may differ from FDA requirements. We may be unable to obtain regulatory approvals in other countries. We may also incur significant costs in attempting to obtain and in maintaining foreign regulatory approvals. If we experience delays in receipt of approvals to market our products outside of the U.S., or if we fail to receive these approvals, we may be unable to market our products or enhancements in international markets in a timely manner, if at all. We currently sell our product in Germany, France, the United Kingdom, Spain, Italy, Mexico, Brazil, Australia and Hong Kong, and may expand into other countries from time to time. We do not know whether orthodontists, dentists and consumers outside our domestic market will adopt Invisalign in sufficient numbers or as rapidly as we anticipate.
Our business exposes us to risks of product liability claims, and we may incur substantial expenses if we are sued for product liability.
Medical devices involve an inherent risk of product liability claims and associated adverse publicity. We may be held liable if any product we develop or any product that uses or incorporates any of our technologies causes injury or is otherwise found unsuitable. Although we intend to continue to maintain product liability insurance, adequate insurance may not be available on acceptable terms and may not provide adequate coverage against potential liabilities. A product liability claim, regardless of its merit or eventual outcome, could result in significant legal defense costs. These costs would have the effect of increasing our expenses and could harm our business.
The market price for our common stock has declined significantly in 2002 and has been highly volatile.
The trading price of our common stock declined in 2002 and has been highly volatile and could be subject to wide fluctuations in price in response to various factors, many of which are beyond our control, including:
In addition, the stock market in general, and the market for technology and medical device companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated to or disproportionate to the operating performance of those companies. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. In the past, following periods of volatility in the market price of a company's securities, class action litigation has often been brought against the company. If a securities class action suit is filed against us, we would incur substantial legal fees and our management's attention and resources would be diverted from operating our business in order to respond to the litigation.
Concentrations of ownership and agreements among our existing executive officers, directors and principal stockholders may prevent other stockholders from influencing significant corporate transactions.
The interest of management could conflict with the interest of our other stockholders. As of September 30, 2002, our executive officers, directors and principal stockholders beneficially owned, in total, approximately 52.3% of our outstanding common stock. These stockholders, if acting together, would be able to influence significantly all matters requiring stockholder approval, including the
election of directors and approval of significant corporate transactions. This could have the effect of delaying or preventing a change of control of the Company, which in turn could reduce the market price of our stock.ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Quantitative Disclosures
We are exposed to market risks inherent in our operations, primarily related to interest rate risk and currency risk. These risks arise from transactions and operations entered into in the normal course of business. We do not use derivatives to alter the interest characteristics of our marketable securities or our debt instruments. We have no holdings of derivative or commodity instruments.
Interest Rate Risk. We are subject to interest rate risks on cash and cash equivalents, available-for-sale marketable securities, existing long-term debts and any future financing requirements. Interest rate risks related to marketable securities are managed by managing maturities in our marketable securities portfolio. Our long-term debt at September 30, 2002 consists only of outstanding balances on lease obligations.
The fair value of our investment portfolio or related income would not be significantly impacted by changes in interest rates since the majority of marketable securities maturities do not exceed twelve months and the interest rates are primarily fixed. Our capital lease obligations of $1.3 million at September 30, 2002 carry fixed interest rates of 6.53% and 11.15% per annum with principle payments due in 60 and 48 equal annual installments, respectively, and which originated in 2000.
Qualitative Disclosures
Interest Rate Risk. Our primary interest rate risk exposures relate to:
We have the ability to hold at least a portion of the fixed income investments until maturity and therefore would not expect the operating results or cash flows to be affected to any significant degree by a sudden change in market interest rates on our short- and long-term marketable securities portfolio.
We manage interest rate risk on our outstanding long-term debts through the use of fixed rate debt. Management evaluates our financial position on an ongoing basis.
Currency Rate Risk. Our primary currency rate risk exposures relate to:
We do not hedge any balance sheet exposures and intercompany balances against future movements in foreign exchange rates. The exposure related to currency rate movements would not have a material impact on future net income or cash flows.
ITEM 4. CONTROLS AND PROCEDURES
Based on their evaluation, as of a date within 90 days of the filing date of this Form 10-Q, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (as defined in Rule 13a-14(c) and 15d-14(c) under the Securities Exchange Act of 1934, as amended) are effective. There have been no significant changes in internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.
PART II. -- OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
On May 1, 2002, GW Com, Inc. filed a complaint in Santa Clara Superior Court against us and James Lindsey, the owner of the premises located at 851 Martin Avenue, Santa Clara, California. We were parties with GW Com to a sub-sublease for such premises, the term of which expired on August 14, 2002. In early 2001, we engaged in negotiations with GW Com to amend the sub-sublease to add additional space and to extend the term through November 30, 2004. The proposed amendment, however, required the consent of the owner of the subject property, Mr. Lindsey. We withdrew from the negotiations of the amendment, after, among other things, Mr. Lindsey's consent could not be obtained. GW Com's complaint against us and Mr. Lindsey alleges breach of contract against us and breach of contract and intentional interference with contract against Mr. Lindsey. In the complaint, GW Com seeks damages of more than $4 million. The complaint is in its early stages and no trial date has been set. We intend to vigorously contest GW Com's allegations.
On April 9, 2002, we exercised our right to terminate an Exclusive Marketing Agreement dated October 18, 2001 with Discus Dental Impressions, Inc. pursuant to the express terms of the Agreement and we issued a press release reporting this termination. On or about May 14, 2002 we received a demand for arbitration submitted by Discus Dental with the American Arbitration Association in San Jose, California. In its arbitration demand, Discus Dental seeks damages of approximately $30 million, including commissions and bonus payments it claims it would have received under the Agreement as well as other expenses, attorneys' fees and injunctive relief to prevent us from selling Invisalign to dentists in the U.S. and Canada. However, prior to terminating the Agreement, we conducted a thorough review of the Agreement and each party's performance thereunder. Based upon that review of the factual and legal issues, we deny all claims made by Discus Dental in its demand and contend that such claims are entirely without merit. In addition, on or about June 13, 2002 we submitted a counter-claim against Discus Dental in the arbitration seeking damages of approximately $40 million arising out of our claims for misrepresentation, breach of confidentiality provisions, and unfair competition, among others. The three arbitrators have been recently selected, and the matter is now set for arbitration on August 18, 2003.
In February 2001 Align Technology was named in a class action lawsuit filed on behalf of all licensed dentists (excluding orthodontists) in the U.S. The complaint alleged that Align Technology's policy of selling Invisalign exclusively to orthodontists violated the U.S. antitrust laws. Without admitting any wrongdoing, the company entered into a Stipulation and Agreement of Settlement with the plaintiffs to settle the lawsuit. The total legal and other settlement costs that Align has agreed to pay are approximately $400,000. Pursuant to the settlement, Align will undertake to train and certify 5,000 general practice dentists each year over the next four years. In November 2001, the Court approved the Stipulation and Agreement of Settlement.
In January 2000, Ormco Corporation filed suit against us asserting infringement of U.S. Patent Nos. 5,447,432 and 5,683,243. The complaint sought unspecified and monetary damages and injunctive relief. In March 2000, we answered the complaint and asserted counterclaims seeking a declaration by the Court of invalidity and non-infringement of the asserted patents.
In June 2000, we entered into a Stipulation of Dismissal with Ormco. Ormco agreed for a period of at least two years not to pursue litigation with respect to these patents, except as set forth below. Further, Ormco agreed that it would not bring any patent action against us for at least a period of one year with respect to any as yet unissued patents. If Ormco were to bring such an action concerning as yet unissued patents after one year, the Stipulation of Dismissal would allow Ormco to include in such an action claims involving U.S. Patent Nos. 5,447,432 and 5,683,243. In August 2001, Ormco notified us of the issuance of U.S. Patent No. 6,244,861 and offered a license for this patent. No assurance can be given that Ormco will not bring another action against us or, that if brought, it will not be successful. Should the suit be recommenced and should our technology be found to infringe, we would have to seek a license from Ormco, which license might not be available on commercially reasonable terms or at all. In that event, we could be subject to damages or an injunction which could materially adversely affect our business. It is possible that, depending on the scope of any new patents that are issued to Ormco, Ormco will bring another patent action after a period of one year has passed.
The claims at issue in the Ormco suit relate to methods and systems for forming and manufacturing custom orthodontic appliances. The relevant claims are limited to the calculation of the final positioning of a patient's teeth based upon a derived or ideal dental archform of the patient. The treatment plan simulation developed in our facilities determines the final positioning of a patient's teeth but is not based on a derived or ideal dental archform of the patient.
From time to time, we have received, and may again receive, letters from third parties drawing our attention to their patent rights. While we do not believe that we infringe any such rights which have been brought to our attention, there may be other more pertinent rights of which we are presently unaware.
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
Use of Proceeds from Sales of Registered Securities. On January 25, 2001 the Securities and Exchange Commission declared effective our Registration Statement on Form S-1 (File No. 333-49932) relating to our initial public offering of our common stock. The 10,000,000 shares offered by us under the Registration Statement were sold at a price of $13.00 per share on January 31, 2001. The managing underwriters for the offering were Deutsche Banc Alex. Brown, Bear, Stearns & Co. Inc., JP Morgan and Robertson Stephens. The underwriters also exercised an overallotment option on March 15, 2001 for 628,706 shares. The overallotment shares were sold at a price of $13.00 per share. The aggregate proceeds to the Company from the offering were $128.5 million after deducting the underwriting discounts and commissions of $9.7 million, and excluding expenses incurred in connection with the offering of approximately $2.3 million.
Of the net proceeds, as of September 30, 2002, we have used net offering proceeds to purchase plant machinery and equipment, leasehold improvements and working capital in the amounts of approximately $24.2 million, $1.6 million and $73.4 million, respectively. No direct or indirect payments were made to directors, officers, general partners of the issuer or their associates, or to persons owning 10% or more of any class of equity securities of the issuer, or to any affiliates of
the issuer in connection with the offering.ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. SUBMISSION OF MATTERS TO VOTE OF SECURITY HOLDERS
None.
ITEM 5. OTHER INFORMATION
None.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
|
Exhibit |
Description of Document |
|
10.18 |
Employment Offer Letter for Roger E. George, Vice President of Legal Affairs & General Counsel |
|
10.19 |
Employment Offer Letter for David S. Thrower, Vice President of Global Marketing |
|
10.20 |
Employment Offer Letter for Eldon M. Bullington, Chief Financial Officer and Vice President, Finance |
|
99.1 |
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
|
99.2 |
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
(b) Reports on Form 8-K
None.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
Align Technology, Inc. (Registrant) |
|
|
Dated: November 13, 2002
|
|
By: |
/s/ Thomas M. Prescott |
|
|
Thomas M. Prescott |
|
|
|
Chief Executive Officer |
|
|
|
By: |
/s/ Eldon M. Bullington |
|
|
Eldon M. Bullington |
|
|
|
Chief Financial Officer and Vice President, Finance |
|
CERTIFICATIONS
I, Thomas M. Prescott, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Align Technology, Inc.;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.
|
Date: November 13, 2002 |
By: |
/s/ Thomas M. Prescott |
|
Thomas M. Prescott |
||
CERTIFICATIONS (continued)
I, Eldon M. Bullington, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Align Technology, Inc.;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.
|
Date: November 13, 2002 |
By: |
/s/ Eldon M. Bullington |
|
|
Eldon M. Bullington |
|||
|
Chief Financial Officer and Vice President, Finance |
|||
INDEX TO EXHIBITS
|
Exhibit |
Description of Document |
|
10.18 |
Employment Offer Letter for Roger E. George, Vice President of Legal Affairs & General Counsel |
|
10.19 |
Employment Offer Letter for David S. Thrower, Vice President of Global Marketing |
|
10.20 |
Employment Offer Letter for Eldon M.Bullington, Chief Financial Officer and Vice President, Finance |
|
99.1 |
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
|
99.2 |
Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |